Pediatric Diabetes and Diabetic Ketoacidosis After COVID-19: Challenges Faced and Lessons Learnt

References

• Park JY, Lee YJ, Kim T, et al. Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea. BMC Cancer. 2020;20(1):1040. doi:10.1186/s12885-020-07544-3
   PubMed Web of Science ®Google Scholar
• Hrynick TA, Ripoll Lorenzo S, Carter SE. COVID-19 response: mitigating negative impacts on other areas of health. BMJ Glob Health. 2021;6(4):e004110. doi:10.1136/bmjgh-2020-004110
   PubMed Web of Science ®Google Scholar
• Jayashree M, Williams V, Iyer R. Fluid therapy for pediatric patients with diabetic ketoacidosis: current perspectives. Diabetes Metab Syndr Obes. 2019;12:2355–2361. doi:10.2147/DMSO.S194944
   PubMed Web of Science ®Google Scholar
• Tittel SR, Rosenbauer J, Kamrath C, et al. Did the COVID-19 lockdown affect the incidence of pediatric type 1 diabetes in Germany? Diabetes Care. 2020;43(11):e172–e173. doi:10.2337/dc20-1633
   PubMed Web of Science ®Google Scholar
• Ho J, Rosolowsky E, Pacaud D, et al. Diabetic ketoacidosis at type 1 diabetes diagnosis in children during the COVID-19 pandemic. Pediatr Diabetes. 2021;22(4):552–557. doi:10.1111/pedi.13205
   PubMed Web of Science ®Google Scholar
• Kamrath C, Rosenbauer J, Eckert AJ, et al. Incidence of type 1 diabetes in children and adolescents during the COVID-19 pandemic in Germany: results from the DPV Registry. Diabetes Care. 2022;45(8):1762–1771. doi:10.2337/dc21-0969
   PubMed Web of Science ®Google Scholar
• Mameli C, Scaramuzza A, Macedoni M, et al. Type 1 diabetes onset in Lombardy region, Italy, during the COVID-19 pandemic: the double-wave occurrence. EClinicalMedicine. 2021;39:101067. doi:10.1016/j.eclinm.2021.101067
   PubMedGoogle Scholar
• Rahmati M, Keshvari M, Mirnasuri S, et al. The global impact of COVID-19 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: a systematic review and meta-analysis. J Med Virol. 2022;94(11):5112–5127. doi:10.1002/jmv.27996
   PubMed Web of Science ®Google Scholar
• Kendall EK, Olaker VR, Kaelber DC, Xu R, Davis PB. Association of SARS-CoV-2 infection with new-onset type 1 diabetes among pediatric patients from 2020 to 2021. JAMA Netw Open. 2022;5(9):e2233014. doi:10.1001/jamanetworkopen.2022.33014
   PubMed Web of Science ®Google Scholar
• Qeadan F, Tingey B, Egbert J, et al. The associations between COVID-19 diagnosis, type 1 diabetes, and the risk of diabetic ketoacidosis: a nationwide cohort from the US using the Cerner Real-World Data. PLoS One. 2022;17(4):e0266809. doi:10.1371/journal.pone.0266809
   PubMed Web of Science ®Google Scholar
• Filippi CM, von Herrath MG. Viral trigger for type 1 diabetes: pros and cons. Diabetes. 2008;57(11):2863–2871. doi:10.2337/db07-1023
   PubMed Web of Science ®Google Scholar
• Müller JA, Groß R, Conzelmann C, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021;3(2):149–165. doi:10.1038/s42255-021-00347-1
   PubMedGoogle Scholar
• Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol. 2020;18(9):2128–2130.e2. doi:10.1016/j.cgh.2020.04.040
   PubMed Web of Science ®Google Scholar
• Kee J, Thudium S, Renner DM, et al. SARS-CoV-2 disrupts host epigenetic regulation via histone mimicry. Nature. 2022;610(7931):381–388. doi:10.1038/s41586-022-05282-z
   PubMed Web of Science ®Google Scholar
• Patterson CC, Harjutsalo V, Rosenbauer J, et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989–2013: a multicentre prospective registration study. Diabetologia. 2019;62(3):408–417. doi:10.1007/s00125-018-4763-3
   PubMed Web of Science ®Google Scholar
• Salmi H, Heinonen S, Hästbacka J, et al. New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic. Arch Dis Child. 2022;107(2):180–185. doi:10.1136/archdischild-2020-321220
   PubMed Web of Science ®Google Scholar
• Gottesman BL, Yu J, Tanaka C, Longhurst CA, Kim JJ. Incidence of new-onset type 1 diabetes among US children during the COVID-19 global pandemic. JAMA Pediatr. 2022;176(4):414–415. doi:10.1001/jamapediatrics.2021.5801
   PubMed Web of Science ®Google Scholar
• Barrett CE, Koyama AK, Alvarez P, et al. Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(2):59–65. doi:10.15585/mmwr.mm7102e2
   PubMed Web of Science ®Google Scholar
• Cherubini V, Grimsmann JM, Åkesson K, et al. Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents. Diabetologia. 2020;63(8):1530–1541. doi:10.1007/s00125-020-05152-1
   PubMed Web of Science ®Google Scholar
• Birkebaek NH, Kamrath C, Grimsmann JM, et al. Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries. Lancet Diabetes Endocrinol. 2022;10(11):786–794. doi:10.1016/S2213-8587(22)00246-7
   PubMed Web of Science ®Google Scholar
• Alfayez OM, Aldmasi KS, Alruwais NH, et al. Incidence of diabetic ketoacidosis among pediatrics with type 1 diabetes prior to and during COVID-19 pandemic: a meta-analysis of observational studies. Front Endocrinol. 2022;13:856958. doi:10.3389/fendo.2022.856958
   PubMed Web of Science ®Google Scholar
• Pillai SS, Cao C, Drees CJ, Chu TC, Mason K, Topor LS. Delays in presentation of new onset diabetes at the start of the COVID-19 pandemic. R I Med J. 2022;105(5):46–50.
   Google Scholar
• Leiva-Gea I, Fernández CA, Cardona-Hernandez R, et al. Increased presentation of diabetic ketoacidosis and changes in age and month of type 1 diabetes at onset during the COVID-19 pandemic in Spain. J Clin Med. 2022;11(15):4338. doi:10.3390/jcm11154338
   PubMed Web of Science ®Google Scholar
• Elgenidy A, Awad AK, Saad K, et al. Incidence of diabetic ketoacidosis during COVID-19 pandemic: a meta-analysis of 124,597 children with diabetes. Pediatr Res. 2022:1–12. doi:10.1038/s41390-022-02241-2
   PubMed Web of Science ®Google Scholar
• Alaqeel A, Aljuraibah F, Alsuhaibani M, et al. The impact of COVID-19 pandemic lockdown on the incidence of new-onset type 1 diabetes and ketoacidosis among Saudi children. Front Endocrinol. 2021;12:669302. doi:10.3389/fendo.2021.669302
   PubMed Web of Science ®Google Scholar
• Zubkiewicz-Kucharska A, Seifert M, Stępkowski M, Noczyńska A. Diagnosis of type 1 diabetes during the SARS-CoV-2 pandemic: does lockdown affect the incidence and clinical status of patients? Adv Clin Exp Med. 2021;30(2):127–134. doi:10.17219/acem/130359
   PubMed Web of Science ®Google Scholar
• Jafari K, Koves I, Rutman L, Brown JC. Impact of the COVID-19 pandemic on the severity of diabetic ketoacidosis presentations in a tertiary pediatric emergency department. Pediatr Qual Saf. 2022;7(2):e502. doi:10.1097/pq9.0000000000000502
   PubMedGoogle Scholar
• Marks BE, Khilnani A, Meyers A, et al. Increase in the diagnosis and severity of presentation of pediatric type 1 and type 2 diabetes during the COVID-19 pandemic. Horm Res Paediatr. 2021;94(7–8):275–284. doi:10.1159/000519797
   PubMedGoogle Scholar
• Mavinkurve M, Jalaludin MY, Chan EWL, et al. Is misdiagnosis of type 1 diabetes mellitus in Malaysian children a common phenomenon? Front Endocrinol. 2021;12:606018. doi:10.3389/fendo.2021.606018
   PubMed Web of Science ®Google Scholar
• Nallasamy K, Jayashree M, Singhi S, Bansal A. Low-dose vs standard-dose insulin in pediatric diabetic ketoacidosis: a randomized clinical trial. JAMA Pediatr. 2014;168(11):999–1005. doi:10.1001/jamapediatrics.2014.1211
   PubMed Web of Science ®Google Scholar
• Williams V, Jayashree M, Nallasamy K, Dayal D, Rawat A. 0.9% saline versus Plasma-Lyte as initial fluid in children with diabetic ketoacidosis (SPinK trial): a double-blind randomized controlled trial. Crit Care. 2020;24(1):1. doi:10.1186/s13054-019-2683-3
   PubMed Web of Science ®Google Scholar
• Chow N, Fleming-Dutra K, Gierke R; CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382–386. doi:10.15585/mmwr.mm6913e2
   PubMed Web of Science ®Google Scholar
• Kountouri A, Korakas E, Ikonomidis I, et al. Type 1 diabetes mellitus in the SARS-CoV-2 pandemic: oxidative stress as a major pathophysiological mechanism linked to adverse clinical outcomes. Antioxidants. 2021;10(5):752. doi:10.3390/antiox10050752
   Web of Science ®Google Scholar
• Benoit SR, Zhang Y, Geiss LS, Gregg EW, Albright A. Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality - United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2018;67(12):362–365. doi:10.15585/mmwr.mm6712a3
   PubMed Web of Science ®Google Scholar
• Stevens JS, Bogun MM, McMahon DJ, et al. Diabetic ketoacidosis and mortality in COVID-19 infection. Diabetes Metab. 2021;47(6):101267. doi:10.1016/j.diabet.2021.101267
   PubMed Web of Science ®Google Scholar
• Pasquel FJ, Messler J, Booth R, et al. Characteristics of and mortality associated with diabetic ketoacidosis among US patients hospitalized with or without COVID-19. JAMA Netw Open. 2021;4(3):e211091. doi:10.1001/jamanetworkopen.2021.1091
   PubMed Web of Science ®Google Scholar
• Khan F, Paladino L, Sinert R. The impact of COVID-19 on Diabetic Ketoacidosis patients. Diabetes Metab Syndr. 2022;16(1):102389. doi:10.1016/j.dsx.2022.102389
   PubMed Web of Science ®Google Scholar
• Priyambada L, Wolfsdorf JI, Brink SJ, et al. ISPAD clinical practice consensus guideline: diabetic ketoacidosis in the time of COVID-19 and resource-limited settings-role of subcutaneous insulin. Pediatr Diabetes. 2020;21(8):1394–1402. doi:10.1111/pedi.13118
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Latif K, Stoever J, et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med. 2004;117(5):291–296. doi:10.1016/j.amjmed.2004.05.010
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care. 2004;27(8):1873–1878. doi:10.2337/diacare.27.8.1873
   PubMed Web of Science ®Google Scholar
• Ersöz HO, Ukinc K, Köse M, et al. Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients. Int J Clin Pract. 2006;60(4):429–433. doi:10.1111/j.1368-5031.2006.00786.x
   PubMed Web of Science ®Google Scholar
• Della Manna T, Steinmetz L, Campos PR, et al. Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis. Diabetes Care. 2005;28(8):1856–1861. doi:10.2337/diacare.28.8.1856
   PubMed Web of Science ®Google Scholar
• Vettoretti M, Cappon G, Acciaroli G, Facchinetti A, Sparacino G. Continuous glucose monitoring: current use in diabetes management and possible future applications. J Diabetes Sci Technol. 2018;12(5):1064–1071. doi:10.1177/1932296818774078
   PubMedGoogle Scholar
• Unger J. Continuous glucose monitoring overview: features and evidence. Am J Manag Care. 2022;28(4 Suppl):S60–S68. doi:10.37765/ajmc.2022.89206
   PubMed Web of Science ®Google Scholar
• Health Quality Ontario. Continuous monitoring of glucose for type 1 diabetes: a health technology assessment. Ont Health Technol Assess Ser. 2018;18(2):1–160.
   Google Scholar
• Hood KK, DiMeglio LA, Riddle MC. Putting continuous glucose monitoring to work for people with type 1 diabetes. Diabetes Care. 2020;43(1):19–21. doi:10.2337/dci19-0054
   PubMed Web of Science ®Google Scholar
• Tauschmann M, Forlenza G, Hood K, et al. ISPAD clinical practice consensus guidelines 2022: diabetes technologies: glucose monitoring. Pediatr Diabetes. 2022;23(8):1390–1405. doi:10.1111/pedi.13451
   PubMed Web of Science ®Google Scholar
• DeSalvo DJ, Miller KM, Hermann JM, et al. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: international comparison from the T1D exchange and DPV initiative. Pediatr Diabetes. 2018;19(7):1271–1275. doi:10.1111/pedi.12711
   PubMed Web of Science ®Google Scholar
• Korytkowski M, Antinori-Lent K, Drincic A, et al. A pragmatic approach to inpatient diabetes management during the COVID-19 pandemic. J Clin Endocrinol Metab. 2020;105(9):dgaa342. doi:10.1210/clinem/dgaa342
   PubMed Web of Science ®Google Scholar
• Bila R, Varo R, Madrid L, Sitoe A, Bassat Q. Continuous glucose monitoring in resource-constrained settings for hypoglycaemia detection: looking at the problem from the other side of the coin. Biosensors. 2018;8(2):43. doi:10.3390/bios8020043
   PubMedGoogle Scholar
• Gherbon A, Frandes M, Timar R, Timar B. The impact of COVID-19 lockdown on glycemic balance in Romanian patients with type 1 diabetes mellitus. Diabetes Metab Syndr Obes. 2022;15:3403–3413. doi:10.2147/DMSO.S386614
   PubMed Web of Science ®Google Scholar
• Scott SN, Fontana FY, Züger T, Laimer M, Stettler C. Use and perception of telemedicine in people with type 1 diabetes during the COVID-19 pandemic-results of a global survey. Endocrinol Diabetes Metab. 2021;4(1):e00180. doi:10.1002/edm2.180
   PubMedGoogle Scholar
• Schiller T, Zornitzki T, Ostrovsky V, et al. Following the COVID-19 experience, many patients with type 1 diabetes wish to use telemedicine in a hybrid format. Int J Environ Res Public Health. 2021;18(21):11309. doi:10.3390/ijerph182111309
   PubMed Web of Science ®Google Scholar
• The Lancet Null. Facing up to long COVID. Lancet. 2020;396(10266):1861. doi:10.1016/S0140-6736(20)32662-3
   PubMed Web of Science ®Google Scholar
• Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193–199. doi:10.1007/s00592-009-0109-4
   PubMed Web of Science ®Google Scholar
• Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–615. doi:10.1038/s41591-021-01283-z
   PubMed Web of Science ®Google Scholar